Appl. No. Filed

09/782,816

February 14, 2001


n and m independently represent 0 or 1, and Xaa is V or L; X1 and X2 are independently defined as follows

X1 is GVKETPQQKYQRLLHEVQELTT (SEQ ID NO: 3), or VKETPQQKYQRLLHEVQELTT (SEQ ID NO: 4), or KETPQQKYQRLLHEVQELTT (SEQ ID NO: 5) or, ETPQQKYQRLLHEVQELTT (SEQ ID NO: 6) or, TPQQKYQRLLHEVQELTT (SEQ ID NO: 7) or, PQQKYQRLLHEVQELTT (SEQ ID NO: 8) or, QQKYQRLLHEVQELTT (SEQ ID NO: 9) or, QKYQRLLHEVQELTT (SEQ ID NO: 10) or, KYQRLLHEVQELTT (SEQ ID NO: 11) or, YQRLLHEVQELTT (SEQ ID NO:12) or, QRLLHEVQELTT (SEQ ID NO: 13) or, RLLHEVQELTT (SEQ ID NO: 14) or, LLHEVQELTT (SEQ ID NO: 15) or, LHEVQELTT (SEQ ID NO: 16) or, HEVQELTT (SEQ ID NO: 17) or, EVQELTT (SEQ ID NO: 18) or, VQELTT (SEQ ID NO: 19) or, QELTT (SEQ ID NO: 20) or, ELTT (SEQ ID NO: 21), or LTT, or TT, or T;

and

X2 is AKQLAAL (SEQ ID NO: 22), or AKQLAA (SEQ ID NO: 23), or AKQLA (SEQ ID NO: 24), or AKQL (SEQ ID NO: 25), or AKQ, or AK, or

Appl. No. Filed



A;

and


Y1 and Y2 are independently defined as follows

Y1 is GEKETPVQKCQRLQIEMNELLN (SEQ ID NO: 26), or EKETPVQKCQRLQIEMNELLN (SEQ ID NO: 27), or KETPVQKCQRLQIEMNELLN (SEQ ID NO: 28), or ETPVQKCQRLQIEMNELLN (SEQ ID NO: 29), or TPVQKCQRLQIEMNELLN (SEQ ID NO: 30), or PVQKCQRLQIEMNELLN (SEQ ID NO: 31), or VQKCQRLQIEMNELLN (SEQ ID NO: 32), or QKCQRLQIEMNELLN (SEQ ID NO: 33), or KCQRLQIEMNELLN (SEQ ID NO: 34), or CQRLQIEMNELLN (SEQ ID NO: 35), or ORLOIEMNELLN (SEQ ID NO: 36), or RLQIEMNELLN (SEQ ID NO: 37), or LQIEMNELLN (SEQ ID NO: 38), or QIEMNELLN (SEQ ID NO: 39), or IEMNELLN (SEQ ID NO: 40), or EMNELLN (SEQ ID NO: 41), or MNELLN (SEQ ID NO: 42), or NELLN (SEQ ID NO: 43), or ELLN (SEQ ID NO: 44), or LLN, or LN, or N; and

Y2 is VATVISTAR (SEQ ID NO: 45), or VATVISTA (SEQ ID NO: 46), or VATVIST (SEQ ID NO: 47), or VATVIS (SEQ ID NO: 48), or VATVI (SEQ ID NO: 49), or VATV (SEQ ID NO: 50), or



(Q (U



VAT, or

VA, or

V, and

derivatives thereof having at least about 90% identity with SEEQ ID NO: 1 or SEQ ID NO: 2.--

Please replace the paragraph beginning at page 5, line 31, with the following rewritten paragraph:

--In a preferred embodiment, the peptide has one of the following sequences: GVKETPQQKYQRLLHEVQELTTEVEKIKTTVKESATEEKLTPVXaaLAKQLAAL (SEQ ID NO: 51), where Xaa is as defined above, or

GEKETPVQKCQRLQIEMNELLNEVAALQVDRKVADEEKQSYDAVVATVISTAR (SEQ ID NO: 52), or has at least about 75%, preferably at least about 80%, more preferably at least about 85%, even more preferably at least about 90%, most preferably at least about 95% identity with one of these sequences. Preferably, the peptide variants contain only conservative amino acid substitutions compared to the reference peptide sequences.--

Please replace the paragraph beginning at page 7, line 4, with the following rewritten paragraph:

--Figure 1 is the amino acid sequence of human p50 (SEQ ID NO: 53), wherein the peptide of SEQ ID NO: 51 (Xaa is L) is bolded and underlined.--

Please replace the paragraph beginning at page 7, line 6, with the following rewritten paragraph:

-- Figure 2 is the partial amino acid sequence of mouse p50 (SEQ ID NO: 54), wherein the peptide of SEQ ID NO: 51 (Xaa is V) is bolded and underlined.--

In the Claims:

Please amend the claims to read as follows: